Pfizer, Astellas prostate cancer drug clears late-stage trial

(Reuters) – Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

The oral drug, Xtandi, in combination with an anti-hormone therapy was more successful than an anti-hormone therapy alone in improving overall survival in men with non-metastatic castration-resistant prostate cancer.

The drug is already approved to treat metastatic castration-resistant prostate cancer.

(This story corrects headline and first paragraph to “prostate” from “prostrate”)

Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza

Our Standards:The Thomson Reuters Trust Principles.

Leave a Reply

Your email address will not be published. Required fields are marked *